Skip to content
Search

Latest Stories

'Community pharmacists acting together to improve pay'

The Pharmacists' Defence Association (PDA) has outlined key outcomes secured by community pharmacists in recent years acting as a trade union to have fairness and equality in rates of pay.

For years, rates of pay for community pharmacists have been reducing in real terms, but factors are changing as a consequence of pharmacists at Boots securing trade union recognition. This historic change has opened up further options for pharmacists to act, said the PDA.


Through PDA union recognition, pharmacists are changing this dynamic, it adds.

The union claims that by securing independent trade union recognition in 2019, those pharmacists employed at Boots have disrupted this status quo, and now the employer must negotiate pay with pharmacists through their representatives.

In 2019, pharmacists supported by experienced union officials submitted a pay claim that called for:

  • Fairness & equality
  • Transparency
  • Respect & RecognitionThey then negotiated a pay settlement that moved towards these goals.  This delivered increases greater than those unilaterally decided by management in the previous year as well as beginning to make improvements to the pay system.

In early 2020 a further increase was negotiated that included removing the lower starting salary for Newly Qualified Pharmacists, a rate that had not been increased for many years.  This gave some pharmacists increases of over 11 per cent.

At the end of 2020, negotiations between company and the pharmacist representatives did not reach a settlement and were escalated to talks with ACAS. Following ACAS’ involvement, a settlement was reached in December, but this did not include a pay increase for most pharmacists.

This result was disappointing for pharmacists, however had they still not been able to negotiate in 2020, just as it was before 2019, there would still have been no pay increases but it is extremely unlikely that the changes which were secured, including removal of the lower pay ranges for those in Northern Ireland, would have happened.

Without union recognition, management would simply have announced in November that there would be no increase due to the pandemic trading conditions and that would have been the end of it.

In addition to the direct impact of pay settlements it is also clear that more pharmacists at Boots are talking about pay and by raising concerns with their line managers some have also received in-year pay increases agreed by local management.

Until pharmacists began negotiating pay through the PDAU, far fewer understood that Boots pay system is based on paying starting salaries which are only 80 per cent of the median average pay paid by competitors and so were less sure what to challenge.

The PDA on-line pay Ready Reckoner allows Boots pharmacists to know where they pay sits in the pay range for their role and is a good basis on which to discuss pay with their line manager

The pay claim for Boots in 2021 seeks to begin to move pay back to its previous real terms value by seeking increases that are above the rate of inflation, this is important following the disappointing 2020 settlement from Boots on top of previous years of sub-inflation increases.

Pharmacists at LloydsPharmacy built upon the efforts of colleagues at Boots and secured their own right to negotiate pay, with the first pay negotiations there set to begin in late 2021 for an early 2022 implementation.

It is in the interest of every pharmacist for the rates of pay for the profession to reflect the value of what pharmacists do.

More For You

Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less